Savara to Present at the Jefferies Global Healthcare Conference
29 Mayo 2024 - 7:05AM
Business Wire
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced that
its management team will participate in a fireside chat at the
Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am
PT/10:00am ET. A live webcast of the fireside chat will be
available on Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for 90 days.
About Savara Savara is a clinical stage biopharmaceutical
company focused on rare respiratory diseases. Our lead program,
molgramostim nebulizer solution, is an inhaled
granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase
3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Molgramostim is delivered via an investigational eFlow® Nebulizer
System (PARI Pharma GmbH). Our management team has significant
experience in rare respiratory diseases and pulmonary medicine,
identifying unmet needs, and effectively advancing product
candidates to approval and commercialization. More information can
be found at www.savarapharma.com. (X, formerly known as Twitter:
@SavaraPharma, LinkedIn:
www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529491002/en/
Savara Inc. IR & PR Anne Erickson
anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024